Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK0610 in Healthy Chinese Adults
NCT06996704Phase 1Completed
- Sponsor
- Ark Biosciences
- Start
- Feb 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AK0610 in respiratory syncytial virus infection (RSV) (7 cohorts), sponsored by Ark Biosciences. Primary endpoint: Incidence and severity of treatment-emergent adverse events up to 361 days. Started Feb 2024; status: completed.
02
Drugs
AK0610
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06996704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06996704.